0.7105
2.67%
-0.0195
After Hours:
.7105
Phio Pharmaceuticals Corp stock is currently priced at $0.7105, with a 24-hour trading volume of 10,374.
It has seen a -2.67% decreased in the last 24 hours and a -3.18% declined in the past month.
The chart indicates a potential bearish trend, as the stock is below the $0.7214 pivot point. If it approaches the $0.6896 support level, significant changes may occur.
Previous Close:
$0.73
Open:
$0.701101
24h Volume:
10,374
Market Cap:
$3.26M
Revenue:
-
Net Income/Loss:
$-11.66M
P/E Ratio:
-0.07
EPS:
-10.156
Net Cash Flow:
$-11.09M
1W Performance:
-4.63%
1M Performance:
-3.18%
6M Performance:
-3.99%
1Y Performance:
-77.44%
Phio Pharmaceuticals Corp Stock (PHIO) Company Profile
Name
Phio Pharmaceuticals Corp
Sector
Industry
Phone
508 767 3861
Address
257 Simarano Drive, Suite 101, Marlborough, MA
Phio Pharmaceuticals Corp Stock (PHIO) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Aug-05-20 | Initiated | H.C. Wainwright | Buy |
Phio Pharmaceuticals Corp Stock (PHIO) Latest News
Phio Pharmaceuticals And 2 Other Stocks Under $2 Insiders Are Buying - Phio Pharma (NASDAQ:PHIO) - Benzinga
Benzinga
Phio Pharmaceuticals CEO buys $740 in company stock By Investing.com - Investing.com
Investing.com
Sypris Solutions And 3 Other Stocks Under $2 Insiders Are Buying - Alset (NASDAQ:AEI) - Benzinga
Benzinga
Phio Pharmaceuticals (NASDAQ:PHIO) Stock Price Up 2.5% - Defense World
Defense World
Market Momentum Report: Phio Pharmaceuticals Corp (PHIO)'s Positive Close at 0.75 – DWinneX - The Dwinnex
The Dwinnex
Phio Pharmaceuticals advances to next dose in cancer trial By Investing.com - Investing.com
Investing.com
Phio Pharmaceuticals Corp Stock (PHIO) Financials Data
Phio Pharmaceuticals Corp (PHIO) Net Income 2024
PHIO net income (TTM) was -$11.66 million for the quarter ending September 30, 2023, a +4.41% increase year-over-year.
Phio Pharmaceuticals Corp (PHIO) Cash Flow 2024
PHIO recorded a free cash flow (TTM) of -$11.09 million for the quarter ending September 30, 2023, a +7.71% increase year-over-year.
Phio Pharmaceuticals Corp (PHIO) Earnings per Share 2024
PHIO earnings per share (TTM) was -$8.156 for the quarter ending September 30, 2023, a +24.24% growth year-over-year.
About Phio Pharmaceuticals Corp
Phio Pharmaceuticals Corp. develops immuno-oncology therapeutics in the United States. It offers INTASYL therapeutic platform focuses on targeting tumor and immune cells by regulating genes of the immune system. The company develops PH-762 that activates immune cells to recognize and kill cancer cells by reducing the expression of the checkpoint protein PD-1 for immunotherapy in adoptive cell transfer (ACT); PH-894 that silences the epigenetic protein BRD4, which is an intracellular regulator of gene expression for use in ACT; and PH-804 that targets the suppressive immune receptor TIGIT, which is a checkpoint protein present on T cells and natural killer cells for use in ACT. It has collaborations with AgonOx Inc. on clinical development of novel T cell-based cancer immunotherapies. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018. Phio Pharmaceuticals Corp. was incorporated in 2011 and is headquartered in Marlborough, Massachusetts.
Cap:
|
Volume (24h):